Revolutionizing Crohn’s Disease Treatment: TRX103 Gains FDA Clearance
Tr1X, a trailblazing biopharmaceutical company, has announced a significant milestone in the fight against treatment-refractory Crohn’s Disease. The FDA has granted clearance for the Investigational New Drug (IND) application of their innovative therapy, TRX103, an allogeneic engineered Tr1 Treg cell therapy. This breakthrough offers new hope for patients who have not responded to conventional treatments. […]
Groundbreaking Progress in GvHD Treatment: Tr1X Successfully Doses First Patient in TRX103 Trial
In an exciting development for autoimmune and inflammatory disorders, Tr1X, Inc. has announced the successful dosing of the first patient in its TRX103-01 proof-of-concept trial. This trial is a significant step forward in the fight against Graft versus Host Disease (GvHD), a serious condition affecting patients undergoing mismatched hematopoietic stem cell transplantation (HSCT). TRX103 represents […]